MARKET

BIOA

BIOA

BioAge Labs Inc.
NASDAQ
25.37
+0.42
+1.68%
Opening 12:30 06/30 EDT
OPEN
24.99
PREV CLOSE
24.95
HIGH
25.50
LOW
24.23
VOLUME
290.45K
TURNOVER
--
52 WEEK HIGH
25.80
52 WEEK LOW
4.065
MARKET CAP
1.13B
P/E (TTM)
-10.5493
1D
5D
1M
3M
1Y
5Y
1D
BioAge Labs (BIOA) Following QUELL CV Trial Start Is The Stock A Bargain
Simply Wall St · 19h ago
Weekly Report: what happened at BIOA last week (0622-0626)?
Weekly Report · 1d ago
BioAge Labs (BIOA) Tests BGE-102 in Phase 2 Trial, But What Does It Signal Strategically?
Simply Wall St · 5d ago
BioAge Labs: Developing A 'Pipeline In A Pill'
Seeking Alpha · 5d ago
Weekly Report: what happened at BIOA last week (0615-0619)?
Weekly Report · 06/22 10:33
BioAge Moves BGE-102 Into Mid-Stage Obesity Heart-Risk Trial, Raising New Investor Focus
TipRanks · 06/18 16:32
Analysts Are Bullish on These Healthcare Stocks: BioAge Labs, Inc. (BIOA), Karyopharm Therapeutics (KPTI)
TipRanks · 06/17 13:30
Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (BIOA) and Viridian Therapeutics (VRDN)
TipRanks · 06/17 11:00
More
About BIOA
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its lead product is BGE-102, a structurally novel, orally available small molecule NLRP3 inhibitor with high potency and brain penetration. In preclinical obesity models, BGE-102 resulted in weight loss as both a monotherapy and in combination with a GLP-1R agonist. Its pipeline includes novel, orally available, brain-penetrant small-molecule NLRP3 inhibitors to treat metabolic diseases and conditions driven by neuroinflammation, as well as novel APJ agonists for metabolic disorders. In preclinical obesity models, APJ agonism has demonstrated the ability to more than double the weight loss induced by a GLP-1R agonist while also restoring healthy body composition and improving muscle function.

Webull offers BioAge Labs, Inc. stock information, including NASDAQ: BIOA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIOA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BIOA stock methods without spending real money on the virtual paper trading platform.